Related Experiment Video
Updated: Jan 24, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Survival Benefit and Safety of Anatomic Resection in Cirrhotic Hepatocellular Carcinoma: Propensity-Matched Analysis
Ao Du1, Hongwei Xu2, Chuang Jiang1
1Department of Liver Surgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China.
Background:
The efficacy of anatomic resection (AR) versus non-anatomic resection (NAR) for hepatocellular carcinoma (HCC) remains controversial, particularly among patients with differing underlying liver conditions. This study aimed to compare the outcomes of AR and NAR in HCC patients with and without liver cirrhosis.
Methods:
We retrospectively analyzed data from HCC patients who underwent hepatectomy at West China Hospital between 2010 and 2022. Patients were stratified based on the presence of liver cirrhosis. Propensity score matching (PSM) was then applied separately within each stratum (cirrhotic and non-cirrhotic) to compare perioperative outcomes and long-term prognosis between AR and NAR.
Results:
A total of 1699 patients were enrolled, including 866 with cirrhosis and 833 without cirrhosis. Before PSM, AR was associated with significantly superior overall survival (OS) and recurrence-free survival (RFS) compared to NAR. Following PSM (1:1 matching based on resection type within each cirrhosis stratum), similar survival advantages for AR were observed. In the matched cirrhotic cohort (255 patients per group), the AR group exhibited significantly better OS (median: 36.5 vs. 25.2 months; p < 0.001) and RFS (median: 26.9 vs. 17.4 months; p < 0.001) compared to the NAR group. Similarly, in the matched non-cirrhotic cohort (284 patients per group), the AR group showed significantly improved OS (median: 36.3 vs. 23.9 months; p < 0.001) and RFS (median: 27.8 vs. 18.5 months; p < 0.001) compared to the NAR group. No significant differences were observed in perioperative outcomes, including postoperative complications and hospital length of stay.
Conclusions:
Compared to NAR, AR improved long-term prognosis in HCC patients. This survival benefit was evident even in cirrhotic patients and was not associated with increased perioperative risks.
Related Concept Videos
Introduction To Survival Analysis
The primary goal of survival analysis is to estimate survival time—the time...
Comparing the Survival Analysis of Two or More Groups
Truncation in Survival Analysis
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
Assumptions of Survival Analysis
Cancer Survival Analysis
Sign Test for Matched Pairs
To conduct the sign test, we first calculate the differences in...

